Life Sciences Sector

An Expert's View about Medical, Health and Cosmetics Products in Canada

Posted on: 29 Aug 2012

Canada has a predominantly publicly financed, privately delivered healthcare system, managed by ten provincial and three territorial health departments.

Life Sciences Sector - Canada Canada has a predominantly publicly financed, privately delivered healthcare system, managed by ten provincial and three territorial health departments. The Federal Government is the Regulator and provider of (tax) transfer payments to the Provinces. Canada maintains 583 core biotechnology development companies and over 200 public sector institutions in the biotechnology field. It is considered the third largest biotechnology market in the world after the US and the UK Market overview The Canadian Government spent $135.1 billion on publicly funded healthcare system; hospitals account for the largest proportion, followed by drugs and physician services. Private insurance and out-of-pocket expenses totalled about $56.6 billion. In 2011, the Canadian medical device market is estimated at US$6.2 billion of which imports amounted to US$4.6 billion. Imports are largely from the USA. Canada’s therapeutic development pipeline includes: ξ Discovery & preclinical 149 ξ Phase I 72 ξ Phase II 77 ξ Phase III 26 ξ Products in the market 42 Canada’s biotechnology sector is primarily concentrated in Ontario 28%, British Columbia 27%, Quebec 21%, followed by the rest of the regions. Major UK investors in Canada include AstraZeneca and GlaxoSmithKline. Key opportunities Healthcare Several fundamental trends continue to affect healthcare: ξ A major shift towards ambulatory, community-based practice. ξ Increased focus on primary and secondary prevention. ξ Providing services/devices for current ‘boomers’ and projected increase in aged Canadian population. ξ Proliferation of co-morbidities and chronic diseases that are stressing the health care system(s). ξ Information technology to better link patients with providers and to bring evidence of treatment effectiveness to both. ξ Innovation adoption to enable faster delivery of healthcare more effectively and efficiently. Biotechnology & Pharmaceuticals ξ R&D and Technology Transfer: Partnerships between UK and Canadian firms and academic institutions can be used to leverage these opportunities. ξ Commercialisation: Opportunities for UK professional services companies that offers consultancy in commercialisation of R&D, proprietary consultancy, technology licensing, technology transfer, joint ventures and project financing to bridge the gap between the critical areas of academia, research and commerce. Production and trials: International production and marketing partners, as well as clinical research organisations that are able to design and undertake clinical trials in the UK for Canadian pharmaceutical firms. Latest export opportunities – Life Sciences Latest export opportunities – Canada Getting into the market Within the Life Sciences sector routes into the Canadian market may vary depending on the product or service being provided. Medical devices are regulated by Health Canada and are classified according to risk (Class I-IV). The usual route into the market is via medical distribution representative supplying into the healthcare sector or hospital buying groups. Biotechnology and pharmaceutical products and services usually enter the market through in- market representation, R&D partnerships, in-market manufacturing, or provision of services direct to the end users. Given the sensitive nature of this sector, establishing relationships in the market is important and can be developed through various routes including attending sector events in the UK, in-market or in third markets. More about doing business in Canada Contacts Market intelligence is critical when doing business overseas, and UKTI can provide bespoke market research and support during overseas visits though our chargeable Overseas Market Introduction Service (OMIS). To commission research or for general advice about the market, get in touch with our specialists in country - or contact your local international trade team. Valerie Strand, Trade Officer (Healthcare) British Consulate-General Toronto T: +1 416 593 1290 x 2229 E: Gilda Carbone, Trade Officer (Biotechnology/Pharmaceuticals) British Consulate-General Toronto T: +1 416 593 1290 x 2224 E: Contact your local international trade team Events itHealthcare Canada 2-4 October 2012 BioContact 3-4 October 2012 Medical Manufacturing Innovations 24,-25 Oct 2012 Health Achieve 5-7 Nov 2012 BioPartnering North America February 2013 BioFinance May 2013 BIO International Convention June 2013 NB: Location differs throughout North America each year. A significant Canadian presence participates in this key industry event. Latest events – Life Sciences Useful links More about OMIS and other UKTI services for exporters
Posted: 29 August 2012

See more from Medical, Health and Cosmetics Products in Canada